Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat...
-
PannTheraPi files Phase 2a trial for epilepsy drug PTI5803, secures EU patent, and appoints Sophie Binay as GM & CSO.
-
Sparian Biosciences initiates a phase 1 clinical trial of SBS-147, its next generation arylepoxamide receptor (AEAr) agonist for acute and chronic pain.
-
LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
-
In a phase 2 trial in Chinese people with T2D, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean weight reduction of up to of up to 9.8% ...
-
LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
Blinded safety data from the ongoing Phase 2 trial suggest no treatment-related amyloid-related imaging abnormalities (ARIA) with PRI-002 Drug Safety and Monitoring Board recommended continued...
-
Dusseldorf, Germany, March 5, 2026 - Priavoid GmbH (“Priavoid”) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085) evaluating its...
-
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...